Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Homology Medicines	BioDelivery Sciences International	Spruce Biosciences	CorMedix	Fulcrum Therapeutics
Symbol	NASDAQ:FIXX	NASDAQ:BDSI	NASDAQ:SPRB	NYSEAMERICAN:CRMD	NASDAQ:FULC
Price Information
Current Price	$7.17	$3.50	$16.13	$9.37	$11.51
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	2.1	1.6	1.2	1.7
Analysis Score	3.4	3.4	3.5	3.5	4.3
Community Score	2.5	3.0	3.9	2.5	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	0.0	0.0	1.7
Earnings & Valuation Score	0.6	2.5	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$27.86	$8.15	$33.25	$19.30	$19.00
% Upside from Price Target	288.52% upside	132.86% upside	106.14% upside	105.98% upside	65.07% upside
Trade Information
Market Cap	$362.00 million	$353.02 million	$375.86 million	$356.29 million	$376.06 million
Beta	-0.24	0.72	N/A	2.71	0.94
Average Volume	509,629	1,257,586	45,223	1,221,822	141,899
Sales & Book Value
Annual Revenue	$1.67 million	$111.39 million	N/A	$280,000.00	N/A
Price / Sales	216.77	3.17	N/A	1,272.45	N/A
Cashflow	N/A	$0.14 per share	N/A	$0.25 per share	N/A
Price / Cash	N/A	24.16	N/A	37.85	N/A
Book Value	$5.73 per share	$0.78 per share	N/A	$0.92 per share	$3.73 per share
Price / Book	1.25	4.49	N/A	10.18	N/A
Profitability
Net Income	$-103,920,000.00	$-15,310,000.00	N/A	$-16,430,000.00	$-82,680,000.00
EPS	($2.47)	$0.10	N/A	($0.89)	($8.13)
Trailing P/E Ratio	N/A	25.00	0.00	N/A	N/A
Forward P/E Ratio	N/A	9.21	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-5,386.00%	10.16%	N/A	-10,214.42%	N/A
Return on Equity (ROE)	-57.92%	25.04%	N/A	-86.52%	-71.94%
Return on Assets (ROA)	-45.33%	9.89%	N/A	-70.16%	-56.24%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.82%	N/A	N/A	N/A
Current Ratio	10.55%	3.16%	7.30%	8.45%	4.99%
Quick Ratio	10.55%	2.80%	7.30%	8.40%	4.99%
Ownership Information
Institutional Ownership Percentage	75.20%	67.40%	N/A	25.91%	72.52%
Insider Ownership Percentage	33.40%	8.57%	N/A	5.00%	30.30%
Miscellaneous
Employees	206	176	17	30	73
Shares Outstanding	50.49 million	100.86 million	23.30 million	38.02 million	32.67 million
Next Earnings Date	5/6/2021 (Estimated)	5/6/2021 (Estimated)	6/28/2021 (Estimated)	5/10/2021 (Estimated)	5/12/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Fulcrum Therapeutics (NASDAQ:FULC) Given "Buy" Rating at HC Wainwright americanbankingnews.com - April 12 at 8:30 AM
	Bicycle Wheels Market Giants Spending Is Going To Boom \| Easton Cycling, Boyd Cycling, Pro Lite industribune.net - April 11 at 10:23 PM
	Sickle cell disease: scientists are developing a game-changing treatment sciencefocus.com - April 10 at 9:12 AM
	Toward a transformative therapy for sickle cell patients news-medical.net - April 10 at 9:12 AM
	Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at ... apnews.com - April 9 at 6:04 PM
	Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference finance.yahoo.com - April 9 at 6:04 PM
	Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at Credit Suisse Group americanbankingnews.com - March 29 at 9:28 AM
	Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development finance.yahoo.com - March 24 at 10:53 AM
	Fulcrum Therapeutics (NASDAQ:FULC) Now Covered by Analysts at Credit Suisse Group americanbankingnews.com - March 22 at 9:04 AM
	Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome ... apnews.com - March 18 at 1:02 PM
	Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference finance.yahoo.com - March 18 at 1:02 PM
	Morgan Stanley Increases Fulcrum Therapeutics (NASDAQ:FULC) Price Target to $12.00 marketbeat.com - March 15 at 8:37 AM
	Fulcrum Therapeutics Inc Registered Shs Equal Weight markets.businessinsider.com - March 10 at 1:23 PM
	Morgan Stanley Maintains Equal-Weight on Fulcrum Therapeutics, Raises Price Target to $12 benzinga.com - March 8 at 6:30 PM
	X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call Transcript seekingalpha.com - March 5 at 5:30 PM
	Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 ... apnews.com - March 5 at 2:28 AM
	Fulcrum Therapeutics Inc Registered Shs Buy markets.businessinsider.com - March 4 at 9:27 PM
	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates finance.yahoo.com - March 4 at 1:40 PM
	Fulcrum Therapeutics Inc to Host Earnings Call finance.yahoo.com - March 4 at 8:39 AM
	Fulcrum Therapeutics Announces CEO Transition finance.yahoo.com - March 4 at 8:39 AM
	Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 4 at 8:39 AM
	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference ... apnews.com - February 27 at 3:13 AM
	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET finance.yahoo.com - February 26 at 7:11 AM
	Fulcrum Therapeutics Recognizes Rare Disease Day 2021 finance.yahoo.com - February 26 at 7:11 AM
	What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares? finance.yahoo.com - February 17 at 1:32 PM
	Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by ... apnews.com - January 22 at 7:43 PM

Date	Company	Brokerage	Action
3/8/2021	Homology Medicines	Stifel Nicolaus	Initiated Coverage
12/14/2020	Homology Medicines	HC Wainwright	Reiterated Rating
8/11/2020	Homology Medicines	Oppenheimer	Lower Price Target
8/10/2020	Homology Medicines	Chardan Capital	Reiterated Rating
6/25/2020	Homology Medicines	Bank of America	Initiated Coverage
6/25/2020	Homology Medicines	FIX	Initiated Coverage
5/13/2020	Homology Medicines	Royal Bank of Canada	Initiated Coverage
3/13/2020	Homology Medicines	Robert W. Baird	Boost Price Target
7/26/2019	Homology Medicines	Canaccord Genuity	Set Price Target
4/11/2019	Homology Medicines	Evercore ISI	Initiated Coverage
5/25/2020	BioDelivery Sciences International	Piper Sandler	Reiterated Rating
5/25/2020	BioDelivery Sciences International	Cantor Fitzgerald	Reiterated Rating
5/25/2020	BioDelivery Sciences International	Roth Capital	Reiterated Rating
4/22/2020	BioDelivery Sciences International	Northland Securities	Initiated Coverage
12/18/2019	BioDelivery Sciences International	SunTrust Banks	Boost Price Target
11/13/2019	BioDelivery Sciences International	LADENBURG THALM/SH SH	Boost Price Target
11/13/2019	BioDelivery Sciences International	Janney Montgomery Scott	Reiterated Rating
9/17/2019	BioDelivery Sciences International	William Blair	Reiterated Rating
3/29/2021	Spruce Biosciences	Credit Suisse Group	Lower Price Target
11/3/2020	Spruce Biosciences	SVB Leerink	Initiated Coverage
11/3/2020	Spruce Biosciences	Cowen	Initiated Coverage
3/2/2021	CorMedix	B. Riley	Reiterated Rating
2/17/2021	CorMedix	Needham & Company LLC	Initiated Coverage
9/29/2020	CorMedix	JMP Securities	Initiated Coverage
9/21/2020	CorMedix	Truist	Initiated Coverage
3/15/2021	Fulcrum Therapeutics	Morgan Stanley	Boost Price Target
8/12/2020	Fulcrum Therapeutics	BTIG Research	Lower Price Target
6/17/2020	Fulcrum Therapeutics	Raymond James	Upgrade

(Data available from 4/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources